Increasing Capacity Using a Cost-Effective, Mature Membrane Chromatography Platform
Already registered? Click here to log in.
Summary
As biopharmaceutical manufacturing moves toward higher productivity, greater molecule complexity, and more flexible operations, traditional resin-based chromatography can become a downstream bottleneck. Long residence times, extended column operations, and high consumable requirements can limit throughput and contribute to manufacturing costs. Membrane chromatography offers a highly efficient, alternative approach, but questions remain around process robustness, scalability, product quality, and applicability to complex molecules.
This webinar will examine how Altruist Biologics’ fully characterized, mature membrane chromatography platform addresses these challenges through rapid-cycling, membrane-based purification. An integrated two-step membrane capture and polishing workflow enables increased downstream productivity while reducing consumable requirements and non-productive processing time. The platform is supported by cross-modality purification data, 200-cycle long-term operational robustness studies, and quantitative economic modeling demonstrating its potential to reduce cost of goods (COGS) in multi-product manufacturing scenarios.
Key Takeaways
-Learn how integrated membrane chromatography can provide a technically robust, linearly scalable industrialization pathway
-Gain insights from Altruist’s own platform case study with a successful validation at 200 L scale
-Assess the applicability of membrane-based purification to complex molecules
Speakers
Dr. Ye Yuan
Senior Director, Head of Process Development
Altruist Biologics
Dr. Ye Yuan is Senior Director and Head of Process Development at Altruist Biologics. A seasoned biotherapeutics CMC leader with over 14 years of industry experience, Dr. Yuan heads the drug substance process development team for antibody and XDC programs at Altruist. Dr. Yuan possesses a deep hands‑on experience covering process development, technology transfer, process validation, GMP manufacturing and contamination‑control strategies. His track record spans the entire product development lifecycle, supporting over 30 IND‑enabling programs and more than 10 NDA/BLA filings. Before joining Altruist, Dr. Yuan took senior managerial roles leading CMC and MSAT teams across multiple biopharma enterprises including Innovent Biologics and Henlius. Dr. Yuan earned his doctoral degree from the University of Science and Technology of China (USTC).
Moderator
